{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T13:02:57Z","timestamp":1793278977509,"version":"4.5.0"},"reference-count":88,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2013,3,19]],"date-time":"2013-03-19T00:00:00Z","timestamp":1363651200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nat Rev Rheumatol"],"published-print":{"date-parts":[[2013,6]]},"DOI":"10.1038\/nrrheum.2013.36","type":"journal-article","created":{"date-parts":[[2013,3,19]],"date-time":"2013-03-19T11:27:45Z","timestamp":1363692465000},"page":"365-374","source":"Crossref","is-referenced-by-count":85,"title":["Management of cancer treatment-induced bone loss"],"prefix":"10.1038","volume":"9","author":[{"given":"Robert E.","family":"Coleman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Rathbone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet E.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,3,19]]},"reference":[{"key":"BFnrrheum201336_CR1","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/S0140-6736(05)74803-0","volume":"365","author":"A Howell","year":"2005","unstructured":"Howell, A.  et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 365, 60\u201362 (2005).","journal-title":"Lancet"},{"key":"BFnrrheum201336_CR2","doi-asserted-by":"publisher","first-page":"2747","DOI":"10.1056\/NEJMoa052258","volume":"353","author":"B Thurlimann","year":"2005","unstructured":"Thurlimann, B.  et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N. Engl. J. Med. 353, 2747\u20132757 (2005).","journal-title":"N. Engl. J. Med."},{"key":"BFnrrheum201336_CR3","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1056\/NEJMoa040331","volume":"350","author":"RC Coombes","year":"2004","unstructured":"Coombes, R. C.  et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N. Engl. J. Med. 350, 1081\u20131092 (2004).","journal-title":"N. Engl. J. Med."},{"key":"BFnrrheum201336_CR4","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1093\/jnci\/dji250","volume":"97","author":"PE Goss","year":"2005","unstructured":"Goss, P. E.  et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J. Natl Cancer Inst. 97, 1262\u20131271 (2005).","journal-title":"J. Natl Cancer Inst."},{"key":"BFnrrheum201336_CR5","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1200\/JCO.2007.11.0726","volume":"26","author":"R Eastell","year":"2008","unstructured":"Eastell, R.  et al. Effect of anastrozole on bone mineral density: 5-year results from the Anastrozole, Tamoxifen, Alone or in Combination trial 18233230. J. Clin. Oncol. 26, 1051\u20131057 (2008).","journal-title":"J. Clin. Oncol."},{"key":"BFnrrheum201336_CR6","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/S1470-2045(07)70003-7","volume":"8","author":"RE Coleman","year":"2007","unstructured":"Coleman, R. E.  et al. Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study. Lancet Oncol. 8, 119\u2013127 (2007).","journal-title":"Lancet Oncol."},{"key":"BFnrrheum201336_CR7","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1056\/NEJMoa041943","volume":"352","author":"VB Shahinian","year":"2005","unstructured":"Shahinian, V. B., Kuo, Y. F., Freeman, J. L. & Goodwin, J. S. Risk of fracture after androgen deprivation for prostate cancer. N. Engl. J. Med. 352, 154\u2013164 (2005).","journal-title":"N. Engl. J. Med."},{"key":"BFnrrheum201336_CR8","doi-asserted-by":"publisher","first-page":"7897","DOI":"10.1200\/JCO.2004.00.6908","volume":"23","author":"MR Smith","year":"2005","unstructured":"Smith, M. R.  et al. Gonadotropin-releasing hormone agonists and fracture risk: a claims-based cohort study of men with non-metastatic prostate cancer. J. Clin. Oncol. 23, 7897\u20137903 (2005).","journal-title":"J. Clin. Oncol."},{"key":"BFnrrheum201336_CR9","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1007\/s00198-007-0543-5","volume":"19","author":"JA Kanis","year":"2008","unstructured":"Kanis, J. A., Johnell, O., Oden, A., Johansson, H. & McCloskey, E. FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos. Int. 19, 385\u2013397 (2008).","journal-title":"Osteoporos. Int."},{"key":"BFnrrheum201336_CR10","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1002\/jbmr.5650070902","volume":"7","author":"LJ Melton","year":"1992","unstructured":"Melton, L. J., Chrischiles, E. A., Cooper, C., Lane, A. W. & Riggs, B. L. Perspective: how many women have osteoporosis? J. Bone Miner. Res. 7, 1005\u20131010 (1992).","journal-title":"J. Bone Miner. Res."},{"key":"BFnrrheum201336_CR11","doi-asserted-by":"crossref","unstructured":"[No authors listed] Who are candidates for prevention and treatment for osteoporosis? Osteoporos. Int. 7, 1\u20136 (1997).","DOI":"10.1007\/BF01623453"},{"key":"BFnrrheum201336_CR12","doi-asserted-by":"publisher","first-page":"2815","DOI":"10.1001\/jama.286.22.2815","volume":"286","author":"ES Siris","year":"2001","unstructured":"Siris, E. S.  et al. Identification and fracture outcomes of undiagnosed low bone mineral density in postmenopausal women: results from the National Osteoporosis Risk Assessment. JAMA 286, 2815\u20132822 (2001).","journal-title":"JAMA"},{"key":"BFnrrheum201336_CR13","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1210\/jc.2011-3045","volume":"97","author":"NB Watts","year":"2012","unstructured":"Watts, N. B.  et al. Osteoporosis in men: an Endocrine Society clinical practice guideline. J. Clin. Endocrinol. Metab. 97, 1802\u20131822 (2012).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"BFnrrheum201336_CR14","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1007\/s00198-007-0343-y","volume":"18","author":"JA Kanis","year":"2007","unstructured":"Kanis, J. A.  et al. The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women. Osteoporos. Int. 18, 1033\u20131046 (2007).","journal-title":"Osteoporos. Int."},{"key":"BFnrrheum201336_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00223-011-9544-7","volume":"90","author":"JA Kanis","year":"2012","unstructured":"Kanis, J. A., McCloskey, E., Johansson, H., Oden, A. & Leslie, W. D. FRAX with and without bone mineral density. Calcif. Tissue Int. 90, 1\u201313 (2012).","journal-title":"Calcif. Tissue Int."},{"key":"BFnrrheum201336_CR16","doi-asserted-by":"publisher","first-page":"196","DOI":"10.3816\/CBC.2010.n.027","volume":"10","author":"CA Saurel","year":"2010","unstructured":"Saurel, C. A., Patel, T. A. & Perez, E. A. Changes to adjuvant systemic therapy in breast cancer: a decade in review. Clin. Breast Cancer 10, 196\u2013208 (2010).","journal-title":"Clin. Breast Cancer"},{"key":"BFnrrheum201336_CR17","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1016\/j.ctrv.2012.02.008","volume":"38","author":"P Hadji","year":"2012","unstructured":"Hadji, P.  et al. Cancer treatment-induced bone loss in premenopausal women: a need for therapeutic intervention? Cancer Treat. Rev. 38, 798\u2013806 (2012).","journal-title":"Cancer Treat. Rev."},{"key":"BFnrrheum201336_CR18","doi-asserted-by":"publisher","first-page":"2373","DOI":"10.1016\/S0959-8049(01)00317-3","volume":"37","author":"L Vehmanen","year":"2001","unstructured":"Vehmanen, L.  et al. Long-term impact of chemotherapy-induced ovarian failure on bone mineral density (BMD) in premenopausal breast cancer patients. The effect of adjuvant clodronate treatment. Eur. J. Cancer 37, 2373\u20132378 (2001).","journal-title":"Eur. J. Cancer"},{"key":"BFnrrheum201336_CR19","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1007\/s10549-010-0899-7","volume":"123","author":"D Cameron","year":"2010","unstructured":"Cameron, D., Douglas, S., Brown, J. & Anderson, R. Bone mineral density loss during adjuvant chemotherapy in pre-menopausal women with early breast cancer: is it dependent on oestrogen deficiency? Breast Cancer Res. Treat. 123, 805\u2013814 (2010).","journal-title":"Breast Cancer Res. Treat."},{"key":"BFnrrheum201336_CR20","doi-asserted-by":"publisher","first-page":"3306","DOI":"10.1200\/JCO.2001.19.14.3306","volume":"19","author":"CL Shapiro","year":"2001","unstructured":"Shapiro, C. L., Manola, J. & Leboff, M. Ovarian failure after adjuvant chemotherapy is associated with rapid bone loss in women with early-stage breast cancer. J. Clin. Oncol. 19, 3306\u20133311 (2001).","journal-title":"J. Clin. Oncol."},{"key":"BFnrrheum201336_CR21","doi-asserted-by":"publisher","first-page":"3205","DOI":"10.1016\/j.ejca.2009.09.026","volume":"45","author":"P Hadji","year":"2009","unstructured":"Hadji, P., Ziller, M., Maskow, C., Albert, U. & Kalder, M. The influence of chemotherapy on bone mineral density, quantitative ultrasonometry and bone turnover in pre-menopausal women with breast cancer. Eur. J. Cancer 45, 3205\u20133212 (2009).","journal-title":"Eur. J. Cancer"},{"key":"BFnrrheum201336_CR22","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1210\/jc.2010-2582","volume":"96","author":"RA Anderson","year":"2011","unstructured":"Anderson, R. A. & Cameron, D. A. Pretreatment serum anti-M\u00fcllerian hormone predicts long-term ovarian function and bone mass after chemotherapy for early breast cancer. J. Clin. Endocrinol. Metab. 96, 1336\u20131343 (2011).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"BFnrrheum201336_CR23","doi-asserted-by":"publisher","first-page":"4628","DOI":"10.1200\/JCO.2002.05.042","volume":"20","author":"W Jonat","year":"2002","unstructured":"Jonat, W.  et al. Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: the Zoladex Early Breast Cancer Research Association Study. J. Clin. Oncol. 20, 4628\u20134635 (2002).","journal-title":"J. Clin. Oncol."},{"key":"BFnrrheum201336_CR24","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1007\/s00198-003-1508-y","volume":"14","author":"I Fogelman","year":"2003","unstructured":"Fogelman, I.  et al. Bone mineral density in premenopausal women treated for node-positive early breast cancer with 2 years of goserelin or 6 months of cyclophosphamide, methotrexate and 5-fluorouracil (CMF). Osteoporos. Int. 14, 1001\u20131006 (2003).","journal-title":"Osteoporos. Int."},{"key":"BFnrrheum201336_CR25","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1016\/S1470-2045(08)70204-3","volume":"9","author":"MF Gnant","year":"2008","unstructured":"Gnant, M. F.  et al. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy. Lancet Oncol. 9, 840\u2013849 (2008).","journal-title":"Lancet Oncol."},{"key":"BFnrrheum201336_CR26","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/S1470-2045(02)00711-8","volume":"3","author":"RM O'Regan","year":"2002","unstructured":"O'Regan, R. M. & Jordan, V. C. The evolution of tamoxifen therapy in breast cancer: selective oestrogen-receptor modulators and downregulators. Lancet Oncol. 3, 207\u2013214 (2002).","journal-title":"Lancet Oncol."},{"key":"BFnrrheum201336_CR27","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1200\/JCO.1996.14.1.78","volume":"14","author":"TJ Powles","year":"1996","unstructured":"Powles, T. J., Hickish, T., Kanis, J. A., Tidy, A. & Ashley, S. Effect of tamoxifen on bone mineral density measured by dual-energy X-ray absorptiometry in healthy premenopausal and postmenopausal women. J. Clin. Oncol. 14, 78\u201384 (1996).","journal-title":"J. Clin. Oncol."},{"key":"BFnrrheum201336_CR28","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1200\/JCO.2005.02.3515","volume":"24","author":"L Vehmanen","year":"2006","unstructured":"Vehmanen, L., Elomaa, I., Blomqvist, C. & Saarto, T. Tamoxifen treatment after adjuvant chemotherapy has opposite effects on bone mineral density in premenopausal patients depending on menstrual status. J. Clin. Oncol. 24, 675\u2013680 (2006).","journal-title":"J. Clin. Oncol."},{"key":"BFnrrheum201336_CR29","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1093\/jnci\/dji372","volume":"16","author":"B Fisher","year":"2005","unstructured":"Fisher, B.  et al. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J. Natl Cancer Inst. 16, 1652\u20131662 (2005).","journal-title":"J. Natl Cancer Inst."},{"key":"BFnrrheum201336_CR30","doi-asserted-by":"publisher","first-page":"2546","DOI":"10.1093\/annonc\/mdr017","volume":"22","author":"P Hadji","year":"2011","unstructured":"Hadji, P.  et al. Management of aromatase inhibitor-associated bone loss in postmenopausal women with breast cancer: practical guidance for prevention and treatment. Ann. Oncol. 22, 2546\u20132555 (2011).","journal-title":"Ann. Oncol."},{"key":"BFnrrheum201336_CR31","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1093\/annonc\/mdq541","volume":"22","author":"R Eastell","year":"2011","unstructured":"Eastell, R.  et al. Long-term effects of anastrozole on bone mineral density: 7-year results from the ATAC trial. Ann. Oncol. 22, 857\u2013862 (2011).","journal-title":"Ann. Oncol."},{"key":"BFnrrheum201336_CR32","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/s10549-010-1121-7","volume":"124","author":"RE Coleman","year":"2010","unstructured":"Coleman, R. E.  et al. Reversal of skeletal effects of endocrine treatments in the Intergroup Exemestane Study. Breast Cancer Res. Treat. 124, 153\u2013161 (2010).","journal-title":"Breast Cancer Res. Treat."},{"key":"BFnrrheum201336_CR33","doi-asserted-by":"publisher","first-page":"224","DOI":"10.3816\/CBC.2010.n.030","volume":"10","author":"LJ Peppone","year":"2010","unstructured":"Peppone, L. J.  et al. Effects of a structured weight-bearing exercise program on bone metabolism among breast cancer survivors: a feasibility trial. Clin. Breast Cancer 10, 224\u2013229 (2010).","journal-title":"Clin. Breast Cancer"},{"key":"BFnrrheum201336_CR34","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1007\/s10549-011-1444-z","volume":"127","author":"K Winters-Stone","year":"2011","unstructured":"Winters-Stone, K.  et al. Strength training stops bone loss and builds muscle in postmenopausal breast cancer survivors: a randomized, controlled trial. Breast Cancer Res. Treat. 127, 447\u2013456 (2011).","journal-title":"Breast Cancer Res. Treat."},{"key":"BFnrrheum201336_CR35","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1007\/s00198-009-1083-y","volume":"21","author":"N Waltman","year":"2010","unstructured":"Waltman, N.  et al. The effect of weight training on bone mineral density and bone turnover in postmenopausal breast cancer survivors with bone loss: a 24-month randomized controlled trial. Osteoporos. Int. 21, 1361\u20131369 (2010).","journal-title":"Osteoporos. Int."},{"key":"BFnrrheum201336_CR36","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/S0140-6736(07)61342-7","volume":"370","author":"BMP Tang","year":"2010","unstructured":"Tang, B. M. P., Eslick, G. D., Nowson, C., Smith, C. & Bensoussan, A. Use of calcium or calcium in combination with vitamin D supplementation to prevent fractures and bone loss in people aged 50 years and older: a meta-analysis. Lancet 370, 657\u2013666 (2010).","journal-title":"Lancet"},{"key":"BFnrrheum201336_CR37","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1056\/NEJMoa1109617","volume":"367","author":"HA Bischoff-Ferrari","year":"2012","unstructured":"Bischoff-Ferrari, H. A.  et al. A pooled analysis of vitamin D dose requirements for fracture prevention. N. Engl. J. Med. 367, 40\u201344 (2012).","journal-title":"N. Engl. J. Med."},{"key":"BFnrrheum201336_CR38","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1634\/theoncologist.2011-0278","volume":"17","author":"T Shao","year":"2012","unstructured":"Shao, T., Klein, P. & Grossbard, M. L. Vitamin D and breast cancer. Oncologist 17, 36\u201345 (2012).","journal-title":"Oncologist"},{"key":"BFnrrheum201336_CR39","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1093\/annonc\/mds277","volume":"24","author":"RE Coleman","year":"2013","unstructured":"Coleman, R. E.  et al. Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-fast study): final 60-month results. Ann. Oncol. 24, 398\u2013405 (2013).","journal-title":"Ann. Oncol."},{"key":"BFnrrheum201336_CR40","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1200\/JCO.2005.05.3744","volume":"25","author":"A Brufsky","year":"2007","unstructured":"Brufsky, A.  et al. Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer. J. Clin. Oncol. 25, 829\u2013836 (2007).","journal-title":"J. Clin. Oncol."},{"key":"BFnrrheum201336_CR41","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1200\/JCO.1997.15.4.1341","volume":"15","author":"S Saarto","year":"1997","unstructured":"Saarto, S.  et al. Chemical castration induced by adjuvant cyclophosphamide, methotrexate, and fluorouracil chemotherapy causes rapid bone loss which is reduced by clodronate: a randomised study in premenopausal patients. J. Clin. Oncol. 15, 1341\u20131347 (1997).","journal-title":"J. Clin. Oncol."},{"key":"BFnrrheum201336_CR42","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1200\/JCO.2009.24.5902","volume":"28","author":"C van Poznak","year":"2010","unstructured":"van Poznak, C.  et al. Prevention of aromatase inhibitor induced bone loss using risedronate: the SABRE trial. J. Clin. Oncol. 28, 967\u2013973 (2010).","journal-title":"J. Clin. Oncol."},{"key":"BFnrrheum201336_CR43","doi-asserted-by":"publisher","first-page":"6336","DOI":"10.1158\/1078-0432.CCR-07-5101","volume":"14","author":"JE Lester","year":"2008","unstructured":"Lester, J. E.  et al. Prevention of anastozole induced bone loss with monthly oral ibandronate during adjuvant aromatase inhibitor therapy for breast cancer. Clin. Cancer Res. 14, 6336\u20136342 (2008).","journal-title":"Clin. Cancer Res."},{"key":"BFnrrheum201336_CR44","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1200\/JCO.2008.19.1783","volume":"27","author":"SL Hines","year":"2009","unstructured":"Hines, S. L.  et al. Phase III randomized, placebo-controlled, double-blind trial of risedronate for the prevention of bone loss in premenopausal women undergoing chemotherapy for primary breast cancer. J. Clin. Oncol. 27, 1047\u20131053 (2009).","journal-title":"J. Clin. Oncol."},{"key":"BFnrrheum201336_CR45","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1007\/s00198-011-1535-z","volume":"23","author":"P Hadji","year":"2012","unstructured":"Hadji, P.  et al. GRAND: the German retrospective cohort analysis on compliance and persistence and the associated risk of fractures in osteoporotic women treated with oral bisphosphonates. Osteoporos. Int. 23, 223\u2013231 (2012).","journal-title":"Osteoporos. Int."},{"key":"BFnrrheum201336_CR46","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1038\/nrclinonc.2011.197","volume":"9","author":"JE Brown","year":"2012","unstructured":"Brown, J. E. & Coleman, R. E. Denosumab in patients with cancer\u2014a surgical strike against the osteoclast. Nat. Rev. Clin. Oncol. 9, 110\u2013118 (2012).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"BFnrrheum201336_CR47","doi-asserted-by":"publisher","first-page":"4875","DOI":"10.1200\/JCO.2008.16.3832","volume":"26","author":"GK Ellis","year":"2008","unstructured":"Ellis, G. K.  et al. Randomised trial of denosumab in patients receiving adjuvant aromatase inhibitors for non-metastatic breast cancer. J. Clin. Oncol. 26, 4875\u20134882 (2008).","journal-title":"J. Clin. Oncol."},{"key":"BFnrrheum201336_CR48","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1200\/JCO.2011.38.7001","volume":"30","author":"K Ito","year":"2012","unstructured":"Ito, K., Blinder, V. S. & Elkin, E. B. Cost effectiveness of fracture prevention in postmenopausal women who receive aromatase inhibitors for early breast cancer. J. Clin. Oncol. 30, 1468\u20131475 (2012).","journal-title":"J. Clin. Oncol."},{"key":"BFnrrheum201336_CR49","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1111\/j.1464-410X.2011.10365.x","volume":"108","author":"CG Roehrborn","year":"2011","unstructured":"Roehrborn, C. G. & Black, L. K. The economic burden of prostate cancer. BJU Int. 108, 806\u2013813 (2011).","journal-title":"BJU Int."},{"key":"BFnrrheum201336_CR50","volume-title":"National Cancer Institute, Bethesda, MD","author":"N Howlader","year":"2012","unstructured":"Howlader, N.  et al. (Eds) SEER Cancer Statistics Review, 1975\u20132009 (Vintage 2009 Populations). National Cancer Institute, Bethesda, MD \n                    [online]\n                    \n                  , (2012)."},{"key":"BFnrrheum201336_CR51","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/nrurol.2010.231","volume":"8","author":"F Labrie","year":"2011","unstructured":"Labrie, F. Blockade of testicular and adrenal androgens in prostate cancer treatment. Nat. Rev. Urol. 8, 73\u201385 (2011).","journal-title":"Nat. Rev. Urol."},{"key":"BFnrrheum201336_CR52","doi-asserted-by":"publisher","first-page":"3337","DOI":"10.1210\/jc.2009-0206","volume":"94","author":"ES LeBlanc","year":"2009","unstructured":"LeBlanc, E. S.  et al. The effects of serum testosterone, estradiol and sex hormone binding globulin levels on fracture risk in older men. J. Clin. Endocrinol. Metab. 94, 3337\u20133346 (2009).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"BFnrrheum201336_CR53","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1159\/000209352","volume":"82","author":"G Novara","year":"2009","unstructured":"Novara, G.  et al. Impact of surgical and medical castration on serum testosterone level in prostate cancer patients. Urol. Int. 82, 249\u2013255 (2009).","journal-title":"Urol. Int."},{"key":"BFnrrheum201336_CR54","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1111\/j.1464-410X.2010.09251.x","volume":"105","author":"JE Brown","year":"2010","unstructured":"Brown, J. E., Sherriff, J. M. & James, N. D. Osteoporosis in patients with prostate cancer on long-term androgen deprivation therapy: an increasing but under-recognized problem. BJU Int. 105, 1042\u20131043 (2010).","journal-title":"BJU Int."},{"key":"BFnrrheum201336_CR55","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1111\/j.1464-410X.2009.08483.x","volume":"104","author":"VK Wadhwa","year":"2009","unstructured":"Wadhwa, V. K., Weston, R., Mistry, R. & Parr, N. J. Long-term changes in bone mineral density and predicted fracture risk in patients receiving androgen-deprivation therapy for prostate cancer, with stratification of treatment based on presenting values. BJU Int. 104, 800\u2013805 (2009).","journal-title":"BJU Int."},{"key":"BFnrrheum201336_CR56","doi-asserted-by":"publisher","first-page":"2042","DOI":"10.1002\/cncr.21047","volume":"103","author":"MM Agarwal","year":"2005","unstructured":"Agarwal, M. M.  et al. Factors affecting bone mineral density in patients with prostate carcinoma before and after orchidectomy. Cancer 103, 2042\u20132052 (2005).","journal-title":"Cancer"},{"key":"BFnrrheum201336_CR57","doi-asserted-by":"publisher","first-page":"e163","DOI":"10.3747\/co.v18i4.746","volume":"18","author":"CE Lee","year":"2011","unstructured":"Lee, C. E.  et al. A comprehensive bone-health management approach for men with prostate cancer receiving androgen deprivation therapy. Curr. Oncol. 18, e163\u2013e172 (2011).","journal-title":"Curr. Oncol."},{"key":"BFnrrheum201336_CR58","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1111\/j.1464-410X.2006.06695.x","volume":"99","author":"J Planas","year":"2007","unstructured":"Planas, J.  et al. The relationship between daily calcium intake and bone mineral density in men with prostate cancer. BJU Int. 99, 812\u2013815 (2007).","journal-title":"BJU Int."},{"key":"BFnrrheum201336_CR59","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1634\/theoncologist.2012-0051","volume":"17","author":"M Datta","year":"2012","unstructured":"Datta, M. & Schwartz, G. G. Calcium and vitamin D supplementation during androgen deprivation therapy for prostate cancer: a critical review. Oncologist 17, 1171\u20131179 (2012).","journal-title":"Oncologist"},{"key":"BFnrrheum201336_CR60","doi-asserted-by":"publisher","first-page":"105","DOI":"10.2165\/11595400-000000000-00000","volume":"12","author":"L Wang","year":"2012","unstructured":"Wang, L., Manson, J. E. & Sesso, H. D. Calcium intake and risk of cardiovascular disease: a review of prospective studies and randomized clinical trials. Am. J. Cardiovasc. Drugs 12, 105\u2013116 (2012).","journal-title":"Am. J. Cardiovasc. Drugs"},{"key":"BFnrrheum201336_CR61","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1056\/NEJMoa010845","volume":"345","author":"MR Smith","year":"2001","unstructured":"Smith, M. R.  et al. Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N. Engl. J. Med. 345, 948\u2013955 (2001).","journal-title":"N. Engl. J. Med."},{"key":"BFnrrheum201336_CR62","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1097\/01.ju.0000063820.94994.95","volume":"169","author":"MR Smith","year":"2003","unstructured":"Smith, M. R.  et al. Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for non-metastatic prostate cancer. J. Urol. 169, 2008\u20132012 (2003).","journal-title":"J. Urol."},{"key":"BFnrrheum201336_CR63","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1200\/JCO.2006.07.3361","volume":"25","author":"MD Michaelson","year":"2007","unstructured":"Michaelson, M. D.  et al. Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer. J. Clin. Oncol. 25, 1038\u20131042 (2007).","journal-title":"J. Clin. Oncol."},{"key":"BFnrrheum201336_CR64","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1016\/j.juro.2006.04.078","volume":"176","author":"CW Ryan","year":"2006","unstructured":"Ryan, C. W., Huo, D., Demers, L. M., Beer, T. M. & Lacerna, L. V. Zoledronic acid initiated during the first year of androgen deprivation therapy increases bone mineral density in patients with prostate cancer. J. Urol. 176, 972\u2013978 (2006).","journal-title":"J. Urol."},{"key":"BFnrrheum201336_CR65","doi-asserted-by":"publisher","first-page":"4426","DOI":"10.1200\/JCO.2007.15.1233","volume":"26","author":"SL Greenspan","year":"2008","unstructured":"Greenspan, S. L.  et al. Skeletal health after continuation, withdrawal, or delay of alendronate in men with prostate cancer undergoing androgen-deprivation therapy. J. Clin. Oncol. 26, 4426\u20134434 (2008).","journal-title":"J. Clin. Oncol."},{"key":"BFnrrheum201336_CR66","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1038\/pcan.2011.4","volume":"15","author":"A Serpa Neto","year":"2012","unstructured":"Serpa Neto, A.  et al. Bisphosphonate therapy in patients under androgen deprivation therapy for prostate cancer: a systematic review and meta-analysis. Prostate Cancer Prostatic Dis. 15, 36\u201344 (2012).","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"BFnrrheum201336_CR67","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1056\/NEJMoa0809003","volume":"361","author":"MR Smith","year":"2009","unstructured":"Smith, M. R.  et al. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N. Engl. J. Med. 361, 745\u2013755 (2009).","journal-title":"N. Engl. J. Med."},{"key":"BFnrrheum201336_CR68","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1016\/j.juro.2010.06.022","volume":"184","author":"MR Smith","year":"2010","unstructured":"Smith, M. R.  et al. Tomerifene to reduce fracture risk in men receiving androgen deprivation therapy for prostate cancer. J. Urol. 184, 1316\u20131321 (2010).","journal-title":"J. Urol."},{"key":"BFnrrheum201336_CR69","doi-asserted-by":"publisher","first-page":"2239","DOI":"10.1016\/j.juro.2011.07.090","volume":"186","author":"MR Smith","year":"2011","unstructured":"Smith, M. R.  et al. Toremifene decreases vertebral fractures in men younger than 80 years receiving androgen deprivation therapy for prostate cancer. J. Urol. 186, 2239\u20132244 (2011).","journal-title":"J. Urol."},{"key":"BFnrrheum201336_CR70","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.eururo.2009.07.049","volume":"57","author":"PA Abrahamsson","year":"2010","unstructured":"Abrahamsson, P. A. Potential benefits of intermittent androgen suppression therapy in the treatment of prostate cancer: a systematic review of the literature. Eur. Urol. 57, 49\u201359 (2010).","journal-title":"Eur. Urol."},{"key":"BFnrrheum201336_CR71","doi-asserted-by":"publisher","first-page":"JC9","DOI":"10.7326\/0003-4819-158-2-201301150-02009","volume":"158","author":"MR Stockler","year":"2013","unstructured":"Stockler, M. R. Intermittent and continuous androgen deprivation did not differ for mortality after radiotherapy for prostate cancer. Ann. Intern. Med. 158, JC9 (2013).","journal-title":"Ann. Intern. Med."},{"key":"BFnrrheum201336_CR72","doi-asserted-by":"publisher","first-page":"1864","DOI":"10.1200\/JCO.2011.38.3745","volume":"30","author":"EY Yu","year":"2012","unstructured":"Yu, E. Y.  et al. Long-term dynamics of bone mineral density during intermittent androgen deprivation for men with non-metastatic, hormone-sensitive prostate cancer. J. Clin. Oncol. 30, 1864\u20131870 (2012).","journal-title":"J. Clin. Oncol."},{"key":"BFnrrheum201336_CR73","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","volume":"364","author":"JS de Bono","year":"2011","unstructured":"de Bono, J. S.  et al. Abiraterone and increased survival in metastatic prostate cancer. N. Engl. J. Med. 364, 1995\u20132005 (2011).","journal-title":"N. Engl. J. Med."},{"key":"BFnrrheum201336_CR74","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1056\/NEJMoa1207506","volume":"367","author":"HI Scher","year":"2012","unstructured":"Scher, H. I.  et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N. Engl. J. Med. 367, 1187\u20131189 (2012).","journal-title":"N. Engl. J. Med."},{"issue":"Suppl. 1","key":"BFnrrheum201336_CR75","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1016\/j.ctrv.2008.03.007","volume":"34","author":"DM Reid","year":"2008","unstructured":"Reid, D. M.  et al. Guidance for the management of breast cancer treatment induced bone loss: a consensus position statement from a UK Expert Group. Cancer Treat. Rev. 34 (Suppl. 1), S3\u2013S18 (2008).","journal-title":"Cancer Treat. Rev."},{"key":"BFnrrheum201336_CR76","doi-asserted-by":"publisher","first-page":"e163","DOI":"10.3747\/co.v18i4.746","volume":"18","author":"CE Lee","year":"2011","unstructured":"Lee, C. E.  et al. A comprehensive bone-health management approach for men with prostate cancer receiving androgen deprivation therapy. Curr. Oncol. 18, e163\u2013e172 (2011).","journal-title":"Curr. Oncol."},{"key":"BFnrrheum201336_CR77","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1056\/NEJMoa0806285","volume":"360","author":"M Gnant","year":"2009","unstructured":"Gnant, M.  et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N. Engl. J. Med. 360, 679\u2013691 (2009).","journal-title":"N. Engl. J. Med."},{"issue":"Suppl.","key":"BFnrrheum201336_CR78","doi-asserted-by":"publisher","first-page":"A520","DOI":"10.1200\/jco.2011.29.15_suppl.520","volume":"29","author":"M Gnant","year":"2011","unstructured":"Gnant, M.  et al. Overall survival with adjuvant zoledronic acid in patients with premenopausal breast cancer with complete endocrine blockade: long-term results from ABCSG-12 [abstract]. J. Clin. Oncol. 29 (Suppl.), A520 (2011).","journal-title":"J. Clin. Oncol."},{"key":"BFnrrheum201336_CR79","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1056\/NEJMoa1105195","volume":"365","author":"RE Coleman","year":"2011","unstructured":"Coleman, R. E.  et al. Breast cancer adjuvant therapy with and without zoledronic acid. N. Engl. J. Med. 365, 1396\u20131405 (2011).","journal-title":"N. Engl. J. Med."},{"key":"BFnrrheum201336_CR80","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1016\/S1470-2045(12)70226-7","volume":"13","author":"AHG Paterson","year":"2012","unstructured":"Paterson, A. H. G.  et al. Oral clodronate for adjuvant treatment of operable breast cancer (National Surgical Adjuvant Breast and Bowel Project protocol B-34): a multicentre, placebo-controlled, randomised trial. Lancet Oncol. 13, 734\u2013742 (2012).","journal-title":"Lancet Oncol."},{"issue":"Suppl. 3","key":"BFnrrheum201336_CR81","first-page":"S2","volume":"71","author":"V Mobus","year":"2011","unstructured":"Mobus, V.  et al. GAIN (German Adjuvant Intergroup Node Positive) Study: a phase-III multicenter trial to compare dose dense, dose intense ETC (iddETC) vs. EC-TX and ibandronate vs. observation in patients with node-positive primary breast cancer\u20141st interim efficacy analysis [abstract]. Cancer Res. 71 (Suppl. 3), S2\u2013S4 (2011).","journal-title":"Cancer Res."},{"key":"BFnrrheum201336_CR82","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/S0140-6736(11)61226-9","volume":"379","author":"MR Smith","year":"2012","unstructured":"Smith, M. R.  et al. Denosumab and bone metastasis-free survival in men with castration-resistant prostate cancer: results of a global phase 3, randomised, placebo-controlled trial. Lancet 379, 39\u201346 (2012).","journal-title":"Lancet"},{"key":"BFnrrheum201336_CR83","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1093\/jnci\/djs263","volume":"18","author":"RE Coleman","year":"2012","unstructured":"Coleman, R. E., Gnant, M., Morgan, G. & Clezardin, P. Effects of bone-targeted agents on cancer progression and mortality. J. Natl Cancer Inst. 18, 1059\u20131067 (2012).","journal-title":"J. Natl Cancer Inst."},{"key":"BFnrrheum201336_CR84","unstructured":"WHO Collaborating Centre for Metabolic Bone Diseases. FRAX: WHO Fracture Risk Assessment Tool \n                    [online]\n                    \n                  , (2013)."},{"key":"BFnrrheum201336_CR85","unstructured":"US National Library of Medicine. Study of denosumab as adjuvant treatment for women with high risk early breast cancer receiving neoadjuvant or adjuvant therapy (D-CARE). ClinicalTrials.gov\n                    [online]\n                    \n                  , (2012)."},{"key":"BFnrrheum201336_CR86","unstructured":"US National Library of Medicine. Study to determine treatment effects of denosumab in patients with breast cancer receiving aromatase inhibitor therapy. ClinicalTrials.gov\n                    [online]\n                    \n                  , (2013)."},{"key":"BFnrrheum201336_CR87","unstructured":"FDA ODAC Briefing Document BLA 125320\/28 Denosumab (Xgeva). February 8th 2012. \n                    [online]\n                    \n                  ."},{"key":"BFnrrheum201336_CR88","unstructured":"Coleman, R. E. & Holen, I. Bone Metastases in Clinical Oncology 4th edn (eds Abeloff, M. D., Armitage, J. O., Niederhuber, J. E., Kastan, M. B. & McKenna, W. G.) (Elsevier, Churchill Livingstone, in the press)."}],"container-title":["Nature Reviews Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nrrheum.2013.36.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrrheum.2013.36","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrrheum.2013.36.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T04:33:13Z","timestamp":1684470793000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrrheum.2013.36"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,3,19]]},"references-count":88,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2013,6]]}},"alternative-id":["BFnrrheum201336"],"URL":"https:\/\/doi.org\/10.1038\/nrrheum.2013.36","relation":{},"ISSN":["1759-4790","1759-4804"],"issn-type":[{"value":"1759-4790","type":"print"},{"value":"1759-4804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,3,19]]}}}